Related Experiment Video
Updated: May 4, 2026
Minimal Erythema Dose MED Testing
Published on: May 28, 2013
Narrowband UVB (311 nm, TL01) phototherapy for pityriasis lichenoides
Kenan Aydogan1, Hayriye Saricaoglu, Hakan Turan
1Department of Dermatology, Faculty of Medicine, Uludag University, Bursa, Turkey. aydogank@uludag.edu.tr
Background/Purpose:
Narrowband (NB) UVB (NB-UVB) phototherapy has recently demonstrated high levels of efficacy and tolerability in a variety of skin diseases. The purpose of the present study was to assess the efficacy of NB-UVB phototherapy in the management of pityriasis lichenoides (PL).
Methods:
The therapeutic response in 31 PL patients (23 pityriasis lichenoides et varioliformis acuta; PLEVA, eight pityriasis lichenoides chronica; PLC) treated with NB-UVB phototherapy between 2000 and 2007 was assessed.
Results:
NB-UVB treatment led to a complete response (CR) in 15 out of 23 PLEVA patients (65.2%) with a mean cumulative dose of 23 J/cm(2) after a mean number of 43.4 exposures and a partial response (PR) in eight patients (34.8%) with a cumulative dose of 15.6 J/cm(2) after a mean number of 32.3 exposures. NB-UVB treatment led to CR in seven out of eight PLC patients (87.5%) with a mean cumulative dose of 18.4 J/cm(2) after a mean number of 45.8 exposures and PR in one patient (12.5%) with a cumulative dose of 9.1 J/cm(2) after a mean number of 19 exposures. Relapses occurred in four PL patients within a mean time period of 6 months.
Conclusion:
NB-UVB therapy is an effective, safe and practical alternative treatment modality for the management of PLEVA and PLC.
